A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas

Brief description of study

The purpose of this study is to find out about the safety and efficacy of CPI-613 in the treatment of metastatic pancreatic cancer when used in combination with a modified dose of a four-drug chemotherapy combination known as FOLFIRINOX.

Clinical Study Identifier: s18-00786
ClinicalTrials.gov Identifier: NCT03504423
Principal Investigator: Paul E. Oberstein
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.